Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.53 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18195172 | 0.80 | ALDH1A1 (0.41) | PDE4AAGO2ALDH1A1KDM4ELMNA | |
| SCHEMBL16302668 | 0.79 | PDE4A (0.57) | PDE4AAGO2ALDH1A1KDM4ELMNA | |
| SCHEMBL26220814 | 0.79 | PDE4A (0.35) | PDE4AAGO2ALDH1A1KDM4ELMNA | |
| SCHEMBL1377855 | 0.72 | PDE4A (0.54) | PDE4AAGO2ALDH1A1KDM4ELMNA | |
| SCHEMBL1381858 | 0.71 | PDE4A (0.73) | PDE4AAGO2ALDH1A1KDM4ELMNA | |
| SCHEMBL12883359 | 0.71 | POLB (0.43) | PDE4AAGO2ALDH1A1KDM4ELMNA | |
| SCHEMBL1828300 | 0.69 | PDE4A (0.74) | PDE4AAGO2ALDH1A1KDM4ELMNA | |
| SCHEMBL11757838 | 0.69 | PDE4A (0.69) | PDE4AAGO2ALDH1A1KDM4ELMNA | |
| Sulfisomidine SCHEMBL34791 | 0.69 | PDE4A (1.00) | PDE4AAGO2ALDH1A1KDM4ELMNA | |
| Sulfisomidine SCHEMBL284793 | 0.68 | PDE4A (0.97) | PDE4AAGO2ALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252841-B2 | Methods of inhibiting bacterial virulence and compounds relating thereto | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-08-28 | — | — | US | disclosed |
| US-20100048573-A1 | Methods of Inhibiting Bacterial Virulence and Compounds Relating Thereto | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048573-A1 | Methods of Inhibiting Bacterial Virulence and Compounds Relating Thereto | MMP8, SLC11A2, NFKBIA | PDE4A 887/4885AGO2 3308/4885ALDH1A1 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.